ES2354360T3 - Anticuerpo anti-interleucina-9 o anticuerpo del receptor anti-interleucina-9 para el tratamiento de la hiperreactividad bronquial. - Google Patents

Anticuerpo anti-interleucina-9 o anticuerpo del receptor anti-interleucina-9 para el tratamiento de la hiperreactividad bronquial. Download PDF

Info

Publication number
ES2354360T3
ES2354360T3 ES05009688T ES05009688T ES2354360T3 ES 2354360 T3 ES2354360 T3 ES 2354360T3 ES 05009688 T ES05009688 T ES 05009688T ES 05009688 T ES05009688 T ES 05009688T ES 2354360 T3 ES2354360 T3 ES 2354360T3
Authority
ES
Spain
Prior art keywords
receptor
interleukin
antibody
dna
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05009688T
Other languages
English (en)
Spanish (es)
Inventor
Nicholas Nicolaides
W. Lee Maloy
Prasad U. Kari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Genaera Corp
Original Assignee
Ligand Pharmaceuticals Inc
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc, Genaera Corp filed Critical Ligand Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2354360T3 publication Critical patent/ES2354360T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5425—IL-9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
ES05009688T 1995-08-24 1996-08-23 Anticuerpo anti-interleucina-9 o anticuerpo del receptor anti-interleucina-9 para el tratamiento de la hiperreactividad bronquial. Expired - Lifetime ES2354360T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US276595P 1995-08-24 1995-08-24
US2765P 1995-08-24
US2380096P 1996-08-06 1996-08-06
US23800P 1996-08-06
EP96929657A EP0846173B1 (en) 1995-08-24 1996-08-23 Use of an anti-interleukin-9 antibody for the preparation of a medicament for the treatment of asthma

Publications (1)

Publication Number Publication Date
ES2354360T3 true ES2354360T3 (es) 2011-03-14

Family

ID=26670837

Family Applications (2)

Application Number Title Priority Date Filing Date
ES05009688T Expired - Lifetime ES2354360T3 (es) 1995-08-24 1996-08-23 Anticuerpo anti-interleucina-9 o anticuerpo del receptor anti-interleucina-9 para el tratamiento de la hiperreactividad bronquial.
ES96929657T Expired - Lifetime ES2249786T3 (es) 1995-08-24 1996-08-23 Uso de un anticuerpo antiinterleuquina 9 para la preparacion de un medicamento para el tratamiento de asma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES96929657T Expired - Lifetime ES2249786T3 (es) 1995-08-24 1996-08-23 Uso de un anticuerpo antiinterleuquina 9 para la preparacion de un medicamento para el tratamiento de asma.

Country Status (10)

Country Link
EP (3) EP2241329A3 (enExample)
JP (3) JP3948495B2 (enExample)
AT (2) ATE484294T1 (enExample)
AU (1) AU6895696A (enExample)
CA (2) CA2666298A1 (enExample)
DE (2) DE69635305T2 (enExample)
DK (2) DK1632248T3 (enExample)
ES (2) ES2354360T3 (enExample)
PT (1) PT1632248E (enExample)
WO (1) WO1997008321A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
EP0942979A2 (en) * 1996-12-02 1999-09-22 Magainin Pharmaceuticals Inc. Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
CA2689842A1 (en) * 1996-12-02 1998-06-11 Genaera Corporation Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
AU5532098A (en) * 1996-12-20 1998-07-17 Magainin Pharmaceuticals, Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
EP1025223A2 (en) * 1997-09-19 2000-08-09 Magainin Pharmaceuticals Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
AU9495798A (en) * 1997-09-19 1999-04-05 Ludwig Institute For Cancer Research Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
CA2370821A1 (en) * 1999-05-01 2000-11-09 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
US20010034062A1 (en) * 2000-02-09 2001-10-25 Scott Koenig Antibody gene therapy with adeno-associated viral vectors
AU2002303098A1 (en) * 2001-02-22 2002-09-12 The Research Foundation Of State University Of New York Opiate receptors
ATE540695T1 (de) 2001-06-08 2012-01-15 Genaera Corp Verfahren zur modulation von il-13
US7582297B2 (en) * 2003-04-11 2009-09-01 Medimmune, Llc Methods of treating respiratory conditions
WO2006012415A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Rage protein derivatives
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
WO2006138429A2 (en) 2005-06-16 2006-12-28 The Feinstein Institute For Medical Research Antibodies against hmgb1 and fragments thereof
US8133859B2 (en) 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent
JP5564167B2 (ja) * 2008-05-22 2014-07-30 日本たばこ産業株式会社 苦味マスキング剤及び苦味低減方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208218A (en) * 1988-09-19 1993-05-04 Ludwig Institute For Cancer Research T cell growth factor glycoproteins
US5414071A (en) 1989-05-23 1995-05-09 Genetics Institute, Inc. Human cytokine IL-9
US5132109A (en) * 1990-10-05 1992-07-21 Ludwig Institute For Cancer Research Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
WO1995027052A1 (en) 1994-03-30 1995-10-12 University Of Maryland At Baltimore Human interleukin variants generated by alternative splicing

Also Published As

Publication number Publication date
JP2011152135A (ja) 2011-08-11
CA2230240A1 (en) 1997-03-06
EP1632248B8 (en) 2010-12-29
EP0846173B1 (en) 2005-10-19
WO1997008321A1 (en) 1997-03-06
EP0846173A1 (en) 1998-06-10
DK1632248T3 (da) 2011-01-24
ES2249786T3 (es) 2006-04-01
CA2666298A1 (en) 1997-03-06
DE69635305T2 (de) 2006-07-06
JP2007169287A (ja) 2007-07-05
EP1632248A1 (en) 2006-03-08
ATE307203T1 (de) 2005-11-15
CA2230240C (en) 2009-08-18
PT1632248E (pt) 2010-12-28
DK0846173T3 (da) 2006-01-16
JP3948495B2 (ja) 2007-07-25
DE69638281D1 (de) 2010-11-25
EP2241329A3 (en) 2011-03-09
JP4813380B2 (ja) 2011-11-09
ATE484294T1 (de) 2010-10-15
EP1632248B1 (en) 2010-10-13
DE69635305D1 (de) 2006-03-02
AU6895696A (en) 1997-03-19
JPH11514851A (ja) 1999-12-21
EP2241329A2 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
US7192578B2 (en) Interleukin-9 mutein peptides
JP4813380B2 (ja) 喘息および関連疾患を含むアトピー性アレルギーを治療するための標的としての喘息関連因子
US7704710B2 (en) Interleukin-9 receptor mutants
US20020156013A1 (en) Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
AU760274B2 (en) Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
AU2003200686B2 (en) Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
AU2007202406B2 (en) Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
ES2347962T3 (es) Biological variability of asthma associated factor, AAF2 (IL-9 receptor), useful in treating and diagnosing atopic allergies including asthma and related disorders.
AU2011265475A1 (en) Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
EP1471144B1 (en) Biological variability of asthma associated factor AAF2 (IL-9 receptor) useful in treating and diagnosing atopic allergies including asthma and related disorders
WO1998027997A1 (en) A method for diagnosis and treatment of inflammatory bowel diseases including crohn&#39;s disease and chronic ulcerative colitis